People

Quality-systems consultant supporting clinical trial execution.

Physician and clinical researcher working on therapies for traumatic brain injury.

Biotechnology executive who announced taking the TIBEAY CEO role after its April 2026 financing.

Tiemo Steinmann is a memodio-affiliated contributor to the2025 preliminary MEMODIO_APP@CARE clinical-trial publication. The primary Alzheimer’s &Dementia abstract spells out his full name and company affiliation, and the European Psychiatry abstract discloses his employment atmemodio GmbH. His published contribution concerns a12-week multidomain app intervention for cognitive impairment. This establishes a dated research-team relationship without inventing a current2026 managerial title, additional qualifications or a personal financing participation.

Valentina Weil is a memodio-affiliated clinical-research collaborator and corresponding author in the2025 published preliminary MEMODIO_APP@CARE trial abstract. The publication identifies memodio GmbH inPotsdam as her institutional affiliation, and the associated European Psychiatry abstract discloses company employment. Her work concerns evaluation of a multidomain app-based intervention for patients with cognitive impairment. The published2025 affiliation is retained with its date qualification; exact current job title, wider career and an authentic portrait remain unverified.

Patrizia Mecocci is a professor of internal medicine and gerontology at the University of Perugia and a member of memodio’s scientific advisory board. Her primary university directory identifies responsibility for theGerontology andGeriatrics section. The university’s biogerontology research profile describes work on ageing, neurodegenerative disease, dementia biomarkers and digital methods for diagnosis and follow-up of cognitive disorders. The company associates her with geriatric expertise in its multimodal digital programme. Her advisory role is separate from university and hospital appointments.

Francesca Mangialasche is a geriatrician and dementia-prevention researcher on memodio’s scientific advisory board. Karolinska Institutet’s current biography identifies her as a senior researcher inNeurobiology, Care Sciences and Society and records doctoral training atKarolinska. Her research covers Alzheimer’s disease, dementia, geriatric epidemiology and multidomain lifestyle interventions. Karolinska’s primary WW-FINGERS material also identifies her scientific coordination work in the international network. The company’s scientific-advisor affiliation does not independently imply a personal equity investment or full-time memodio employment.

Arnim Quante is a psychiatrist and scientific advisor to memodio. The company abbreviates his name as A.Quante and identifies his work at the Friedrich von Bodelschwingh clinic inBerlin. The clinic’s own2026 programme confirms his full name and senior role directing its centre for older-person psychiatry and psychotherapy. His teaching covers dementia diagnosis, prevention and treatment and psychopharmacology in older adults. This resolves the abbreviation to Arnim rather than a guessed Andreas or Alexander namesake. The memodio role is advisory.

Gereon Nelles is a neurologist and scientific advisor to memodio. Primary professional-association material establishes his neurological clinical background; the company lists him on its scientific advisory board. The German Clinical Trials Register identifies him at NeuroMed Campus inCologne as the scientific contact for the MEMODIO_APP@CARE exploratory trial, with memodio GmbH as sponsor. He is a named author of published preliminary trial results. His clinical-research and advisory relationships are distinguished from company employment and from any unproven personal investment.

Daphne Teo is a historical co-founder of Engine Biosciences, identified in the contemporaneous2018 issuer announcement republished by EDBI. Nest.Bio’s current directory identifies her as a partner and NSG BioLabs CEO. Founding affiliation does not imply a current operating role at Engine. Goodman Capital’s archived May2019 primary team directory additionally identifies Daphne Teo as Co-founder and Managing Director (historical published affiliation). This Singapore firm invested its principals’ and families’ capital; the role is source-qualified historical and does not imply a currently held appointment or personal cash investment.

Hu Li is an Engine Biosciences scientific founder and adviser. His Mayo Clinic research uses systems pharmacology, regulatory-network analysis and machine learning to support individualized medicine.

Martina Heer is a nutritional-physiology specialist named on memodio’s scientific advisory board. The company identifies her contribution in nutrition research, while a primary university biography records doctoral training in nutritional science and research at the German Aerospace Center on space physiology and nutrition. She has contributed to research on metabolism and nutrition in unusual physiological conditions. Her company listing supports an advisory role in the app’s nutritional component; the older Bonn institutional title is retained as company-published background rather than automatically assigned as a current university appointment.

Prashant Mali is an Engine Biosciences scientific founder and adviser. His UC San Diego research covers synthetic biology, regenerative medicine and tools for gene- and cell-based therapies, including CRISPR genome engineering.

Stefan Schneider is a movement and neuroscience researcher on memodio’s scientific advisory board. The German Sport University Cologne identifies him within its Institute of Movement and Neurosciences. His primary research biography describes study of neurocognitive and neuroaffective performance in extreme environments, and the relationship between physical exercise, brain activity and health. His training includes sport science and doctoral research in sensorimotor adaptation. The memodio affiliation is scientific advice on a multimodal intervention rather than an assumed full-time company appointment.

José Iglesias is an Engine Biosciences clinical scientific adviser. His oncology-development experience includes HiberCell, Boston Biomedical and Biothera, including translational medicine and early clinical programmes.

George Trainor is an Engine Biosciences scientific adviser with experience in medicinal chemistry, discovery strategy and development of drug candidates across oncology, antivirals, neuroscience and inflammation.

Elke Kalbe is a medical-psychology and neuropsychology professor named on memodio’s scientific advisory board. The University Hospital Cologne’s primary directory identifies her as head of Medical Psychology, Neuropsychology and Gender Studies. Her academic expertise is relevant to cognitive assessment and psychological aspects of neurological disease. The company lists her advisory contribution to its digital cognitive-health programme. The role is separate from her university employment; an advisory listing is not treated as proof of company shares or an individual financing participation.

Nicholas A. Saccomano, PhD, is a Modulo Bio board director announced inJuly2025 and previously disclosed inNovember2024. The issuer describes four decades of drug discovery experience, including leadership at OnKure, Pfizer, Array BioPharma and SomaLogic. He earned a Columbia organic chemistry PhD and a SUNY Buffalo bachelor’s degree. Those career titles are source-dated to the announcement rather than asserted as current2026 employment. Retained earlier biography: Nicholas A. Saccomano advises Engine Biosciences on drug discovery. His earlier positions included Pfizer’s Boulder research-site leadership, chief scientific officer at Array Biopharma and chief technology officer at SomaLogic. He holds a Columbia organic-chemistry doctorate.

James Collins is a scientific founder and founding scientific advisory co-chair of Engine Biosciences. A synthetic-biology researcher at MIT, he develops engineered biological systems with applications in infections, antibiotic discovery and cellular behaviour.

Maria Cristina Polidori is a physician and clinical ageing researcher on memodio’s published scientific advisory board. Primary professional material identifies her as professor and head of clinical ageing research at the University of Cologne. She earned her medical degree at the University of Perugia, undertook research at Massachusetts General Hospital and Boston University, specialised in geriatrics and completed academic qualification inGermany. Her work focuses on ageing mechanisms, healthy ageing and the care of older patients. Her company affiliation is advisory, not an employment or personal-investment claim.

Joy Ho is last published as an Engine Biosciences board observer representing EDBI in April2026. Her background includes healthcare investing, a lung-cancer programme at Genome Institute of Singapore, molecular-engineering research and Genentech manufacturing. Current EDBI primary directory additionally lists her as Associate Principal in the Healthcare investment team; the earlier Engine Biosciences observer affiliation and its historical qualification remain preserved.

Paul Zimmermann is a software engineer and co-founder of memodio, responsible for technical leadership and app development. The company’s current founder biography describes his involvement from the initial concept to the finished product, with emphasis on reliability, usability and support for patients and families. Its2023 funding announcement identifies him as an HPI software engineer. He formed the company with physicians Doron Stein and Felix Bicu. No additional corporate appointments or personal investment amounts are inferred from his founding role.

Ali Farahanchi is last published as an Engine Biosciences director in April2026. The directory identifies his managing-director affiliation with Camford Capital and prior research and consulting in semiconductor and healthcare industries. His graduate training includes MIT and Chicago.

Felix Bicu is a physician, memory trainer and co-founder of memodio. His own company biography describes work on cognitive activation and support for family caregivers, drawing on clinical experience and care for a grandfather with dementia. The2023 issuer funding announcement also identifies him as founder and public-relations contact. He is affiliated with memodio in the2025 MEMODIO_APP@CARE research abstract, connecting the company’s product development with clinical investigation. His exact broader clinical speciality and current management title are not expanded beyond the primary sources.

Doron Benjamin Stein is a physician, co-founder and chief executive of memodio GmbH. The company’s legal disclosure identifies Dr.Doron B.Stein as its authorised representative; its first financing announcement names him CEO. He helped develop the app’s digital, non-drug approach to mild cognitive impairment and early dementia and contributed to the white paper on care for early Alzheimer’s disease. His founder biography connects his interest in earlier cognitive care to dementia in his family. The company was founded with Felix Bicu and software engineer Paul Zimmermann inPotsdam inDecember2021.

Karsten Witt is last published as Engine Biosciences’ clinical-development leader in April2026. His oncology and inflammatory-disease experience includes Black Diamond Therapeutics, Array Biopharma, OSI, Gilead, NeXstar and Amgen. He earned his medical degree in Copenhagen.

David M. Epstein was an Engine Biosciences scientific adviser from2017 and additionally served in R&D leadership from2023. His background included Black Diamond Therapeutics, Duke-NUS and OSI Pharmaceuticals. Engine subsequently publicly announced his death in2026; his affiliation here is historical, with exact death day undisclosed.

Yaron Turpaz joined Engine Biosciences in2018 and is last published as CIO in its April2026 directory. Earlier informatics leadership included Human Longevity, AstraZeneca, Eli Lilly and Affymetrix. He trained in bioengineering at Illinois and business at Chicago Booth.

Robert Abraham is last published as Engine Biosciences’ chief scientific officer in its April2026 directory. He previously led cancer biology at Odyssey Therapeutics, served as Vividion CSO and held oncology research leadership at Pfizer and Wyeth.

Jeffrey Lu co-founded and leads Engine Biosciences. His earlier career included Bain and AirAsia, and founding or leadership work at Enleofen Bio, PairX Bio and travel-technology company AAE. He holds a University of Pennsylvania BA. This is the biotech entrepreneur, distinct from the a16z and Aberdeen namesakes. Goodman Capital’s archived May2019 primary team directory additionally identifies Jeffrey Lu as Co-founder (historical published affiliation). This Singapore firm invested its principals’ and families’ capital; the role is source-qualified historical and does not imply a currently held appointment or personal cash investment.

HCC external adviser and former Blue Cross and Blue Shield of North Carolina chief executive, described as CEO emeritus since 2017. His background includes law, public policy and healthcare governance; he studied at Appalachian State, Duke and Wake Forest.

Physician, hospitalist and HCC external adviser. He co-founded the Society of Hospital Medicine, held medical leadership responsibilities at Remedy, and developed clinical decision-support and natural-language-processing technology through Zato Health.

HCC external adviser with healthcare technology commercialization experience. His career includes Cigna and ActiveHealth Management, whose clinical decision-support business was acquired by Aetna. He studied economics at Trinity.

HCC external adviser with health-insurer and hospital finance experience, including Blue Cross and Blue Shield of Louisiana, Novant and Deloitte. She is a certified public accountant and studied at LSU and Tulane.

HCC external adviser and retired Duke University Health System chief financial officer. He retired in 2020; earlier experience includes Loyola, Mission and Tulane health systems and the U.S. Army. The biography spells his given name Kenneth despite a directory-heading typo.

HCC external adviser with healthcare operations and finance experience. Published career history includes Health Advocate, Magellan, Aetna, Cigna and Deloitte. He studied accounting at Notre Dame.

HCC external adviser with healthcare investing, finance and accounting experience. His published background includes Merrill Lynch private equity, health-plan financial work and an NYU MBA.

Isabelle Schein is identified by Labcorp in its March 30, 2026 healthcare AI white paper as director of new ventures and strategic alliances. She represents the corporate venture program’s role connecting scientific, technology and clinical partners; Labcorp’s November 2025 Getlabs interview also publishes this affiliation. A complete own career biography, authenticated portrait and any later promotion are not verified, so this role preserves the exact dated own publication rather than assuming a newer external-directory title.

HCC external adviser and former chief executive of Lifetime Healthcare Companies, retired in 2012. His published experience includes Excellus BlueCross BlueShield and healthcare governance. This individual is distinct from Click Therapeutics CEO David Benshoof Klein.

Megann Vaughn Watters leads Labcorp’s strategic corporate venture investing and new ventures and strategic alliances. Labcorp’s January 2026 Teal Health interview and AOA Dx’s January 2026 report identify her venture leadership; her 2026 Precision Med Tri-Conference speaker listing confirms Vice President, New Ventures and Strategic Alliances. Her published event biography describes experience identifying healthcare technologies, executing partnerships, equity investments and licensing, managing alliances and serving on venture-backed boards. Before Labcorp she was a U.S. Patent and Trademark Office medical-device patent examiner and conducted tissue-engineering research at Humacyte. She earned an MBA and a BSE in biomedical engineering at Duke University.

HCC external adviser with provider-network, bundled-payment and healthcare technology experience at Oxford, Cigna and Remedy. HCC identifies him as its ReferWell board designee. He studied technology management at MIT and chemistry at Cornell.

HCC external adviser whose published background centers on community healthcare and Open Door Family Medical Centers, with interests in access and digital care. She attended St. Lawrence and earned an MBA from Pace.

HCC external adviser with health-plan finance and operations experience. His career includes Florida Blue, Health Options and Cigna. He studied actuarial science and business at Michigan and Washington University.

Certified public accountant listed as an HCC external adviser. Her published career includes senior finance, administration and strategy responsibilities at Highmark and health-services board work. External affiliations are source-published career history, not a verified current employer roster.

Physician listed in HCC’s external advisory network. His published career spans clinical practice, health-plan and pharmaceutical operations, and leadership or advisory work with Ascension, the Advisory Board, Oliver Wyman and Vanguard.

HCC external adviser with insurance and healthcare investment experience. His published career includes leadership of Universal American and RAB Ventures. He studied law at Columbia and attended Swarthmore.

Physician and healthcare entrepreneur listed in HCC’s external advisory network. His published background covers biotechnology, medical technology and consumer health, including Celex, SolasCure, Gelmetix and Kind Consumer; he holds a Harvard MBA.

Published HCC external adviser with a healthcare insurance leadership background, including UnitedHealthcare commercial businesses and Anthem healthcare services. These outside positions are career history published by HCC, rather than independently asserted current appointments.

HCC chief financial officer appointed in 2025, corroborated by its April 2026 adviser filing. A certified public accountant, she previously worked at Goode Partners, Galen Partners and Marks Paneth and Shron, and studied accounting and taxation at NYU.

HCC principal with experience in healthcare operations, investing and investment banking. Prior roles include CareATC strategy, IMC Health, Comvest and RBC. He holds a Wharton healthcare-management MBA and a Michigan business degree.

HCC chief compliance officer, also associated with outsourced compliance provider Pillar Compliance Group. His background includes private-fund compliance at First Republic and work with ACA and Kroll. The April 2026 adviser filing corroborates his compliance responsibility.

HCC associate who joined in 2025 following healthcare investment banking at Cain Brothers. He studied finance at Indiana University with a computer-science minor.

HCC partner responsible for strategic alliances and corporate limited-partner relationships. Her prior experience includes healthcare equity research at Wells Fargo, Leerink Swann and ABN AMRO, consulting at Arthur Andersen, and hospital finance at Massachusetts General Hospital.

Till Ikemann joined Living Brain in2019 as technical co-founder and CTO. His game-development training and experience building a games business informed the company’s VR rehabilitation software. The issuer’s2022 press kit documents responsibility for technical development. He is absent from the current team directory; the CTO appointment is retained as historical with no inferred current employment or departure date.

Barbara Stegmann co-founded Living Brain with Julian Specht in2019 while studying psychology. The company’s 2022 seed press kit and2023 founder biography identify her as CEO, responsible for economic and strategic development. The current legal notice identifies Julian as managing director and the present team directory does not list Barbara; her former CEO role is therefore historical, with no assumed departure date.

Thomas Böhme is a 3D artist on Living Brain’s current public team, supporting its virtual-reality rehabilitation environments. The employer’s exact named card and portrait establish the role.

Mégane Maillot is a 3D artist on Living Brain’s current public team, contributing to virtual rehabilitation environments. The portrait is published immediately alongside her named card and uses the Megan_V1 filename; its copied Christian alt label is a website metadata error rather than evidence of a second Christian identity.

Mariam Raad is a software developer on Living Brain’s current published team. The current role title supersedes an older Unity Intern label in the source image alt. The named company-published photograph is preserved without inferring additional qualifications.

Christian Gavenea is a software developer on Living Brain’s current published team, contributing to the company’s virtual-reality rehabilitation software. His current card uses Software Developer; the portrait alt refers to an earlier Junior Unity Developer title.

Julian Specht is managing director, Chief Scientific Officer and co-founder of Living Brain. The current legal notice confirms his management authority and the current team card identifies CSO and co-founder. He studied business psychology, gained early experience at SAP and develops scientifically grounded cognitive rehabilitation inspired by his own experience of neurological disease.

HCC founder and managing partner who leads its investment committee. His healthcare research career includes Credit Suisse, Goldman Sachs and Citi, following technology consulting at Accenture. He studied engineering at Cornell and analytic finance and statistics at Chicago.

Kathryn E. Wengel Director Kathryn E. Wengel has served as a director of the Company since March 25, 2021. Ms. Wengel has served as the Executive Vice President, Chief Technical Operations & Risk Officer of Johnson & Johnson, a leading healthcare company, since January 2023, and as an Executive Committee member and an Executive Officer of Johnson & Johnson since July 2018. Ms. Wengel has significant healthcare, operations, and global business expertise, with more than three decades of experience in leadership positions at Johnson & Johnson in the United States and various locations globally, including as its Worldwide VP and then Executive Vice President, Chief Global Supply Chain Officer from March 2014 through December 2022, and its first Chief Quality Officer from April 2010 until March 2014. Ms. Wengel has served as the Chair of the Board of Directors at the National Association of Manufacturers in the U.S. and is a member of their Executive Committee, as well as a member of the Board of GS1 Global, a nonprofit that develops and maintains global supply chain standards. Ms. Wengel holds a Bachelor of Science in Engineering degree in civil engineering and operations research from Princeton University.

John H. Sampson, MD, PhD, MHSc, MBA Director John H. Sampson has served as a director of the Company since February 9, 2026. Dr. Sampson is the Richard D. Krugman Endowed Chair, Vice Chancellor for Health Affairs, Dean of the University of Colorado Anschutz School of Medicine, and President of CU Medicine. Prior to serving at the University of Colorado, he was Senior Vice Present in the Duke University Health System and led the Duke Health Integrated Practice. As a nationally recognized neurosurgeon, physician-scientist and academic leader, Dr. Sampson brings extensive experience spanning clinical care, biomedical research, medical education and large-scale health system leadership. He is a practicing neurosurgeon and has authored nearly 300 peer-reviewed publications, with a long track record of research focused on advancing new therapies for neurologic disease. Dr. Sampson was born in Canada and holds a Bachelor of Science degree and an MD from the University of Manitoba. He is a member of the National Academy of Medicine, American Society for Clinical Investigation, and the Association of American Physicians.

Richelle P. Parham Director, Chairperson of the Compensation and Human Capital Committee Richelle Parham has served as a director of the Company since February 8, 2016 and Chairperson of the Compensation and Human Capital Committee since June 2023. Ms. Parham previously served as President of Global eCommerce and Business Development for Universal Music Group, a music-based entertainment company, a position she has held from June 2021 to June 2025. In October 2019, Ms. Parham became a Managing Director of WestRiver Group, which provides integrated capital solutions to the global innovation economy with investments focused on technology, life sciences, energy, and experiential sectors. She previously served as a General Partner at Camden Partners, a private equity firm, from October 2016 to October 2019. Prior to Camden Partners, Ms. Parham served as Chief Marketing Officer of eBay from November 2010 to March 2015. Ms. Parham was responsible, globally, for developing eBay brand strategy and brand marketing to reach 108+ million active eBay users. Prior to joining eBay, Ms. Parham served as head of Global Marketing Innovation and Initiatives and head of Global Marketing Services at Visa Inc. from 2008 to 2010. Her experience also includes 13 years at Digitas, Inc., a leading marketing agency, where she held a variety of senior leadership roles, including senior vice president and general manager of the agency’s Chicago office. Ms. Parham has served as a Director of Best Buy Co., Inc. since March 2018. She served on the board of directors for e.l.f. Beauty, Inc. from March 2018 to June 2022 and Scripps Network Interactive Inc. from 2012 until March 2018, when Scripps Network Interactive was acquired by Discovery Communications. Ms. Parham holds double Bachelor of Science degrees in business administration and design arts from Drexel University. She became a member of the Drexel University board of trustees in 2014.

Kirsten M. Kliphouse Director Kirsten M. Kliphouse has served as a director of the Company since October 12, 2022. Ms. Kliphouse previously served as the President of Google Cloud Americas, a public cloud vendor that offers a suite of computing services, a position she held from March 2022 to June 2023, where she was responsible for leading and growing the sales, go-to-market, customer engagement, channel, and services organizations. At Google Cloud, she also served as the Global Chair of the Aspiring Leadership Academy and Women@Google Cloud. Prior to her position as President, Ms. Kliphouse served as President of the North American division of Google Cloud from June 2019 to March 2022. Prior to Google Cloud, Ms. Kliphouse was Senior Vice President at Red Hat, Inc., a subsidiary of International Business Machines Corporation, Chief Executive Officer of Yardarm Technologies, a hardware and software solutions company, and founder and Chief Executive Officer of Scaling Ventures, a technology investment and advisory firm. Prior to her position at Yardarm, Ms. Kliphouse spent more than 25 years at Microsoft, Inc., where she was part of the executive leadership team and held numerous executive positions in Enterprise Sales, Original Equipment Manufacturers (OEM), Partner and Channels, and as Corporate Vice President of Customer Support, Success and Professional Services, during which she led more than 10,000-employees globally. Ms. Kliphouse is a recipient of the Founders Award for her superior leadership and contributions to the business. Ms. Kliphouse has served as a director of Global Payments, Inc. since October 2023. Ms. Kliphouse previously served as a director of Dun & Bradstreet Holdings, Inc. from July 2023 to August 2025 and also served as a director of Vimeo, Inc. from June 2025 until the Company’s acquisition in November 2025. Ms. Kliphouse holds a degree in Computer Information Sciences and Business from Muhlenberg College.

Jeffrey A. Davis Director, Chair of the Audit Committee Jeffrey A. Davis has served as a director of the Company since December 1, 2019, and Chairman of the Audit Committee since June 2023. Mr. Davis previously served as the Chief Financial Officer of Dollar Tree, Inc. from October 2022 through March 2025. Prior to his time at Dollar Tree, Inc., Mr. Davis served as Chief Financial Officer of Qurate Retail Group, a leading retailer and media conglomerate comprised of eight retail brands including QVC, HSN and Zulily, from October 2018 through August 2022. Prior to Qurate Retail Group, Mr. Davis served as Chief Financial Officer of J. C. Penney Company Inc., a retail company, from July 2017 until September 2018. Prior to joining J. C. Penney, Mr. Davis served as Chief Financial Officer of Darden Restaurants Inc., a restaurant operator, from July 2015 until March 2016 and Chief Financial Officer of the Walmart U.S. segment of Walmart Inc. from January 2014 to May 2015, and in various other positions of increasing responsibility at Walmart U.S. from 2006 to 2013. Mr. Davis previously served on the Board and Audit Committee of Massmart Holdings Limited (MSM: Johannesburg Stock Exchange), a South African retailer, from 2011 to 2014, on the Board of Visitors for the Wake Forest University School of Business from 2015 to 2017, and on the Board of Visitors for the Joseph M. Katz Graduate School of Business at the University of Pittsburgh from 2010 to 2016. Mr. Davis’ experience also includes nine years in senior executive roles at Lakeland Tours LLC and McKesson Corporation. Mr. Davis holds a bachelor’s degree in accounting from the Pennsylvania State University and a master’s degree in business administration from the Joseph M. Katz Graduate School of Business at the University of Pittsburgh. Mr. Davis is a certified public accountant (inactive) and has received a CERT Certificate in Cyber-Risk Oversight from the Carnegie Mellon University Software Engineering Institute as part of the National Association of Corporate Directors’ Cyber-Risk Oversight Program.

Victor Bulto Director Victor Bulto has served as a director of the Company since December 1, 2025. Mr. Bulto is President of Novartis US and a member of the Novartis Executive Committee since April 2022. In this role, he leads a bold strategy to reimagine medicine and improve patient care in the world’s largest healthcare market. Mr. Bulto has spearheaded commercial transformation and championed the integration of technology, advanced analytics, real-world evidence and early detection strategies to accelerate access and improve patient outcomes. With more than two decades at Novartis, he has held senior roles across major therapeutic areas and several geographies, including President of U.S. Pharmaceuticals, Head of U.S. Alcon Pharmaceuticals, and Head of the Neuroscience Franchise for Region Europe. Mr. Bulto holds a Master’s in Health Economics and Pharmacoeconomics and a Postgraduate Degree in Pharmaceutical Marketing from Universitat Pompeu Fabra. He earned his MBA from ESADE and completed the Advanced Management Program at Harvard Business School. He also holds a Master’s in Chemical Engineering and a Bachelor of Science in Chemistry from Institut Químic de Sarrià in Spain.

Pete Wilder is listed by Oxford Science Enterprises as Head of Property & Operations. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Peter Weston-Smith is listed by Oxford Science Enterprises as Senior Associate, HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Katherine Ward is listed by Oxford Science Enterprises as Operating Partner, HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Kerrii B. Anderson Director Kerrii B. Anderson has served as a director of the Company since May 17, 2006. Ms. Anderson is the former Chief Executive Officer, President and Chief Financial Officer of Wendy’s International. Prior to joining Wendy’s in 2000, she was senior vice president and chief financial officer for 14 years for M/I Homes, Inc., a public company that builds single-family homes. Ms. Anderson has served as a director of Abercrombie & Fitch Co. since February 2018, The Sherwin-Williams Company since April 2019, and Worthington Industries, Inc. since September 2010. She was previously a director of the board of Chiquita Brands International from 2009 to 2012, and was chairwoman of the board from 2012 until the company’s acquisition in 2015. She was also a member of the board of P.F. Chang’s China Bistro from 2009 to 2012. Ms. Anderson also serves on the boards of the following non-profit entities: The Columbus Foundation and Elon University Board of Trustees. Ms. Anderson has received a CERT Certificate in Cyber-Risk Oversight from the Carnegie Mellon University Software Engineering Institute as part of the National Association of Corporate Directors’ Cyber-Risk Oversight Program.

Sami Walter is listed by Oxford Science Enterprises as Senior Associate, Deep Tech. The published affiliation belongs to the Deep Tech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Wallace Wallace is listed by Oxford Science Enterprises as Senior Associate, Independent Investments. The published affiliation belongs to the Independent team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Jon Wall is listed by Oxford Science Enterprises as Portfolio Talent Lead, Deep Tech. The published affiliation belongs to the Deep Tech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

George Todd is listed by Oxford Science Enterprises as Principal, Deep Tech. The published affiliation belongs to the Deep Tech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Bernard Taylor is listed by Oxford Science Enterprises as Non-Executive Director. The published affiliation belongs to the Board team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Jack Strudley is listed by Oxford Science Enterprises as Head of Finance. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Andrew Straiton is listed by Oxford Science Enterprises as Senior Associate, Deep Tech. The published affiliation belongs to the Deep Tech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Molly Stevens is listed by Oxford Science Enterprises as Non-Executive Director. The published affiliation belongs to the Board team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Katya Smirnyagina is listed by Oxford Science Enterprises as Advisor, Life Sciences. The published affiliation belongs to the Life Sciences team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Joel Schoppig is listed by Oxford Science Enterprises as Partner, HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Heather Roxborough is listed by Oxford Science Enterprises as Senior Partner, Head of HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Satoko Robertson is listed by Oxford Science Enterprises as Executive Assistant & Legal Secretary. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

John Roberts is listed by Oxford Science Enterprises as Senior Compliance Manager. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Katharina Ramshorn is listed by Oxford Science Enterprises as Senior Associate, Life Sciences. The published affiliation belongs to the Life Sciences team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Andy Penfold is listed by Oxford Science Enterprises as Content Lead. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Sive Ozer is listed by Oxford Science Enterprises as Head of Legal, Investing. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Richard Oakley is listed by Oxford Science Enterprises as Principal, Deep Tech. The published affiliation belongs to the Deep Tech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Matt Nicholls is listed by Oxford Science Enterprises as Advisor. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Gaëlle Newton is listed by Oxford Science Enterprises as Events Manager. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Matt Myers is listed by Oxford Science Enterprises as Senior Associate, Independent Investments. The published affiliation belongs to the Independent team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Jeff Moore is listed by Oxford Science Enterprises as Senior Partner, Head of Life Sciences. The published affiliation belongs to the Life Sciences team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established. Jeff Moore, also published as Jeffrey B. Moore and legally Jeffrey Bernard Moore, formerly led MP Healthcare Venture Management as President. Oxford Science Enterprises’ September 29, 2026 announcement confirms his move to Senior Partner and Head of Life Sciences and describes MPH as his preceding position. He led early-stage biotechnology investments from academic discovery to exit, including Covagen, F-star, Korro Bio, miRagen, Genocea and Trimtech. His current Oxford affiliation is preserved; historical MPH biographies must not be treated as proof of a current MPH presidency. He holds a DPhil from Oxford, an MBA from MIT and a biology degree from the University of New Brunswick; his career includes infectious-disease postdoctoral work at Harvard Medical School, Research Corporation Technologies, Millennium and Scriptgen. The exact final day of MPH employment is not established.

Alicia Mederick is listed by Oxford Science Enterprises as Team Co-ordinator. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Rachel McKee is listed by Oxford Science Enterprises as Senior People Advisor. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Emily Matthews is listed by Oxford Science Enterprises as Responsible Investment & ESG Manager. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Oliver Mahony is listed by Oxford Science Enterprises as Partner, Independent Investments. The published affiliation belongs to the Independent team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Jeanette Lovis is listed by Oxford Science Enterprises as Executive Assistant. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Tatiana Lobanov-Rostovsky is listed by Oxford Science Enterprises as Associate, HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Céline Leclere is listed by Oxford Science Enterprises as Executive Assistant, HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Snigdha Lal is listed by Oxford Science Enterprises as Associate, Deep Tech. The published affiliation belongs to the Deep Tech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Lauren Laing is listed by Oxford Science Enterprises as Principal, HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Daoud Khan is listed by Oxford Science Enterprises as Finance Manager. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Matthew Hunt is listed by Oxford Science Enterprises as Legal Counsel. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Richard Hobbs is listed by Oxford Science Enterprises as Non-Executive Director. The published affiliation belongs to the Board team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Jon Hepple is listed by Oxford Science Enterprises as Advisor, Life Sciences. The published affiliation belongs to the Life Sciences team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Julia Wang Executive Vice President and Chief Financial Officer Julia Wang has served as Executive Vice President and Chief Financial Officer of Labcorp since December 2024. Prior to joining Labcorp, Julia served as CFO of BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) since 2021, which she joined in 2020 as Senior Vice President, Enterprise Optimization and Deputy CFO. While at BeiGene, she was instrumental in driving business transformations through accelerating growth, nurturing innovation and cultivating a culture of sustainable operating efficiencies. Julia served as Senior Vice President, Global Business Finance and Corporate Planning at Alexion Pharmaceuticals prior to BeiGene. Before Alexion, she held leadership positions at Quest Diagnostics (NYSE: DGX), including Vice President of Finance, U.S. Regional Business and Enterprise Commercial, and Vice President of Finance, Value Creation. Julia held senior leadership roles at Johnson & Johnson (NYSE: JNJ) as CFO of various operating businesses in medical device and pharmaceuticals earlier in her career. Previously, she led finance initiatives at PepsiCo. Julia earned her MBA from Fuqua School of Business at Duke University and her BA in British Language and Literature from Shandong Normal University.

Sam Harris is listed by Oxford Science Enterprises as Senior Associate, Capital Formation & Investor Relations. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Sam Harman is listed by Oxford Science Enterprises as Partner, Head of Deep Tech. The published affiliation belongs to the Deep Tech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Marlou Hanselmann is listed by Oxford Science Enterprises as Communications & Digital Marketing Executive. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Alex Hammacher is listed by Oxford Science Enterprises as Head of Strategic Operations & Corporate Finance. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Clare Gumbley is listed by Oxford Science Enterprises as Portfolio Talent Lead, Life Sciences. The published affiliation belongs to the Life Sciences team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

William Goodlad is listed by Oxford Science Enterprises as Advisor, Deep Tech. The published affiliation belongs to the Deep Tech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Paul Galluzzo is listed by Oxford Science Enterprises as Entrepreneur-in-Residence, HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

James Finlayson is listed by Oxford Science Enterprises as Entrepreneur-in-Residence, Deep Tech. The published affiliation belongs to the Deep Tech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Martin Fiennes is listed by Oxford Science Enterprises as Advisor, Deep Tech. The published affiliation belongs to the Deep Tech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Polly Elvin is listed by Oxford Science Enterprises as Partner, Capital Formation & Investor Relations. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Peter Donnelly is listed by Oxford Science Enterprises as Non-Executive Director. The published affiliation belongs to the Board team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Iwona Dombek-Wieczorek is listed by Oxford Science Enterprises as Finance Officer. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Nick Dixon-Clegg is listed by Oxford Science Enterprises as Partner, Head of Independent Investments. The published affiliation belongs to the Independent team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Sally Dewhurst is listed by Oxford Science Enterprises as Principal, Life Sciences. The published affiliation belongs to the Life Sciences team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Sanne De Jongh is listed by Oxford Science Enterprises as Partner, Life Sciences. The published affiliation belongs to the Life Sciences team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Andre Crawford-Brunt is listed by Oxford Science Enterprises as Non-Executive Director. The published affiliation belongs to the Board team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Harry Clifford is listed by Oxford Science Enterprises as Entrepreneur-in-Residence, HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Chris Chambers is listed by Oxford Science Enterprises as Non-Executive Chairman. The published affiliation belongs to the Board team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Liliane Chamas is listed by Oxford Science Enterprises as Principal, HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Mark Chadwick is listed by Oxford Science Enterprises as Scientist-in-Residence, Deep Tech. The published affiliation belongs to the Deep Tech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Lilly Bussmann is listed by Oxford Science Enterprises as Partner. The published affiliation belongs to the Deep Tech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Claire Brown is listed by Oxford Science Enterprises as Partner, Life Sciences. The published affiliation belongs to the Life Sciences team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Athene Blakeman is listed by Oxford Science Enterprises as General Counsel. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Tony Besse is listed by Oxford Science Enterprises as Principal, HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Lisa Bedwell is listed by Oxford Science Enterprises as Head of Marketing. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Charo Bajo is listed by Oxford Science Enterprises as Data & Projects Manager. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Nico Babaian is listed by Oxford Science Enterprises as Entrepreneur-in-Residence, HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Benny Axt is listed by Oxford Science Enterprises as Entrepreneur-in-Residence, HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Christopher Ashton is listed by Oxford Science Enterprises as Advisor, Life Sciences. The published affiliation belongs to the Life Sciences team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Suzanne Algie is listed by Oxford Science Enterprises as Team Co-Ordinator, Life Sciences. The published affiliation belongs to the Life Sciences team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Antonia Jenkinson is listed by Oxford Science Enterprises as Chief Financial Officer. The published affiliation belongs to the Executive team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Jack Edmondson is listed by Oxford Science Enterprises as Chief Investment Officer. The published affiliation belongs to the Executive team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Ed Bussey is listed by Oxford Science Enterprises as Chief Executive Officer. The published affiliation belongs to the Executive team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Bryan Vaughn Executive Vice President and President, Diagnostics Bryan Vaughn is Executive Vice President & President, Diagnostics at Labcorp, where he oversees the company’s operating divisions and commercial growth strategy. Bryan joined Labcorp in 2009, and since that time, has held multiple leadership roles. Most recently, he served as Senior Vice President, Health Systems & Mid-America Division, leading diagnostic operations across 19 states and managing enterprise partnerships with health systems and national accounts. He has led Labcorp’s health system growth strategy since 2017. Previously, he served as Vice President of Finance for Labcorp’s Atlantic Division, and earlier, Director of Women’s Health Segment Marketing and Director of Strategic Planning and Corporate Development, where he helped shape business strategy, drive product development and expand Labcorp’s market presence. Before joining Labcorp, Bryan worked in healthcare investment banking at Raymond James, a leading financial services firm, and in health advocacy at Cigna, a global health services company. Bryan holds a Bachelor of Arts in economics from Vanderbilt University and a Master of Business Administration with a concentration in health sector management from Duke University’s Fuqua School of Business.

Amy Summy EVP, Chief Marketing Officer and Consumer Health Lead Amy Summy has served as EVP, Chief Marketing Officer and Consumer Health Lead at Labcorp since March 2020. She is responsible for global marketing including brand, go-to-market strategy, omnichannel marketing, ecommerce, commercialization, product management, and communications. She also leads the company’s consumer health business under the brands Labcorp OnDemand and Ovia Health. Amy is a member of Labcorp’s Environmental, Social and Governance (ESG) and Venture Fund Steering Committees, and serves as the Executive Sponsor for EnABLE (an Employee Resource Group for people with disabilities). Prior to Labcorp, Amy was a partner with Ernst & Young (EY), where she led EY Digital’s Marketing and Insights Practice from 2018 to 2020. She joined EY from TE Connectivity a global manufacturer of connector and sensor technologies, where she was SVP and CMO and a member of TE’s Operating Committee. At TE, she led the transformation of the brand and customer facing functions, embedding digital capabilities and data in the marketing, product introduction, sales and service processes. She developed and launched TE’s ecommerce business, aimed at small- and mid-size customers in North America, Europe and China. Prior to TE, Amy held executive roles at global digital consultancy Sapient during the company’s growth from 300 employees to over 10,000 employees and $1B in revenue. As Senior Vice President and Managing Director, she led the New York, West Coast and financial services businesses. Amy began her career at Dun & Bradstreet. Amy serves as a board member of the San Diego Natural History Museum, board observer of venture-backed NowDx, and a member of the Corporate Council of the Children’s Hospital of Philadelphia. She holds a Bachelor of Business Administration in finance from Kent State University and a Master of Business Administration in finance and international business from the Stern School of Business at New York University.

Bola Oyegunwa, Ph.D. EVP, Chief Information and Technology Officer Bola Oyegunwa, Ph.D., has served as Labcorp’s Executive Vice President and Chief Information and Technology Officer since November 2024. Since joining Labcorp in 2019 as Vice President of Decentralized Clinical Trials Technology, Bola has pioneered advancements in remote clinical trials technology, significantly enhancing patient accessibility to trials. He went on to serve as Chief Information Officer for Labcorp’s Drug Development segment, where he led digital transformation, expanded robotic process automation, and developed technology solutions for investigators and sponsors alike. In his most recent role as Senior Vice President of Enterprise Systems, Data & Technology, Bola directed essential functions such as laboratory systems, corporate systems, robotics, and data engineering. His leadership delivered transformative technology solutions across Labcorp’s Diagnostics and Biopharma Laboratory Services segments. Before Labcorp, Bola held leadership positions as Global Head of Virtual Trials Technology and Director of Corporate Strategy at IQVIA, and Global Head of Corporate and Digital Strategy at Cenduit. He has also advised private equity and venture capital firms and served as a board advisor for Headlands Research, a KKR portfolio company. Bola holds a Doctorate in Microbiology and Immunology, a Master’s in Microbial Biotechnology, and an MBA from North Carolina State University.

Jon Meltzer, Ph.D. Executive Vice President, Chief Operations Officer Jon Meltzer, Ph.D., is Executive Vice President, Chief Operations Officer at Labcorp, where he oversees the company’s diagnostics lab operations, global supply chain, and enterprise strategy. Jon joined Labcorp in 2006 and has held leadership roles of increasing responsibility. Most recently, he served as Senior Vice President of Laboratory Operations, leading operations across more than 30 laboratory locations and oversight of the P&Ls for the Esoteric business units. Previously, he held a series of senior leadership roles, including Senior Vice President of Strategy, Senior Vice President of Esoteric Businesses, Senior Vice President of Specialty Oncology, and Vice President of Corporate Development, in which role he managed licensing, partnerships, mergers and acquisitions, and led the Labcorp Venture Fund. Jon also played a pivotal role in Labcorp’s pandemic response, directing efforts that delivered more than 70 million COVID-19 PCR tests and supported next-generation sequencing surveillance for the U.S. Centers for Disease Control and Prevention. Before joining Labcorp, Jon worked in venture capital, the Duke Office of Licensing and Ventures, and the North Carolina Department of the State Treasurer. Earlier in his career, he served as a Technology Commercialization Officer at the National Research Council of Canada and co-founded a company manufacturing molecular reagents for biomedical research. Jon holds his Bachelor of Science and a Doctorate in Anatomy from the University of Manitoba and a Master of Business Administration from Duke University’s Fuqua School of Business.

Anita Graham EVP and Chief Human Resources Officer Anita Graham has served as Executive Vice President and Chief Human Resources Officer since 2023. Before joining Labcorp, Anita served as Executive Vice President, Chief Human Resources Officer and Public Affairs at VF Corporation, one of the world’s largest lifestyle-focused footwear and apparel companies. In addition to leading the human resources function through major business transformations, she oversaw the company’s public affairs initiatives, including corporate communications, government relations, community relations and the VF Foundation. Prior to VF, Anita served as Senior Vice President, Chief Human Resources and Administration Officer at ADT Corporation, where she led the human resources, environment, health and safety, and corporate communications functions. Previously, she was the Executive Vice President, Chief Administrative Officer at Shire plc, a global biopharmaceutical company that is now part of Takeda Pharmaceuticals. Anita currently holds board-level roles in several professional organizations including the Human Resources Policy Association, the Center on Executive Compensation and the Center on Executive Succession. She is also a member of the national board for The Trust for Public Lands. She holds a Bachelor of Science in industrial and labor relations from Cornell University and a Master of Business Administration in finance from the Stern School of Business at New York University.

Kathryn W. Kyle Executive Vice President, Chief Legal Officer and Corporate Secretary Kathryn Kyle has served as Executive Vice President, Chief Legal Officer and Corporate Secretary at Labcorp since January 2026. Kathryn joined Labcorp in 2003 in the litigation group and has advanced through broader leadership roles in the law department since that time, becoming General Counsel in 2016. Under her leadership, Labcorp has successfully managed major litigation matters and reorganized various legal functions, including intellectual property areas and professional liability claims. Kathryn also successfully introduced legal support technology into core legal functions and provided critical strategic support to the enterprise during crisis events, including the Covid-19 pandemic. Prior to joining Labcorp, Kathryn was a Senior Corporate attorney with Polaroid Corporation, where she was primarily responsible for employment and labor issues. She previously served as a litigation associate at a western Massachusetts law firm. Kathryn received her Bachelor’s degree from Smith College and her Juris Doctorate from Emory University School of Law.

Adam Schechter Chairman, President, and Chief Executive Officer Adam Schechter became Chief Executive Officer of Labcorp in 2019 and Chairman of the Board in May 2020. Prior to that, he was named Lead Independent Director after serving as a director of the company since 2013. Before joining Labcorp, Mr. Schechter held a variety of senior leadership positions at Merck & Co., Inc. He was Executive Vice President and President of Merck’s Global Human Health Division from 2010 to 2018 leading the company’s worldwide pharmaceutical and vaccine businesses. In this role, he was also a member of Merck’s executive committee. Prior to becoming President of Merck’s Global Human Health Division, Mr. Schechter served as President of Merck’s global pharmaceutical business from 2007 to 2010. His extensive experience at Merck also included global and U.S.-focused leadership roles spanning sales, marketing and managed markets, as well as business and product development. Mr. Schechter has been a Board Member for DaVita Inc. since 2022, and he serves on the Board for Water.org. He also serves as the American Clinical Laboratory Association (ACLA) Board Vice-Chair, and a member of the Corporate Advisory Council for the National Alliance for Hispanic Health. In 2025, Mr. Schechter joined the Board of Project HOPE, a leading global health and humanitarian organization. Previously, he served on the Boards of the European Federation of Pharmaceutical Industries and Associations (EFPIA), where he led the Policy and Access Committee, the Healthcare Leadership Council and the Merial Animal Health Company. Mr. Schechter holds a Bachelor of Science degree in biology and an honorary Doctorate of Humane Letters degree from La Salle University in Philadelphia, Pennsylvania.

Helmut C. Nanz is named in PatrickPfeffer’s own2025 ACPHealthtech launch announcement as an investment collaborator; his own reply confirms involvement in that journey. The available primary evidence does not specify a current employee title, partner legal appointment or individual LP amount. This profile records the named affiliation with those limits and does not merge him with unrelated family members or infer a private check.

Bjoern von Siemens is a Caresyntax cofounder and investor. PatrickPfeffer names him among the collaborators behind the2025 ACPHealthtech launch; ACP’s own announcement separately names the vonSiemensfamily as an anchor investor. This is a qualified investment affiliation, not proof that Bjoern personally supplied a particular LP commitment or held an unspecified operatingjob. Caresyntax’s July2025 ownannouncement confirms his continuing board and capital-market/corporate-development work after MattKrueger became CEO.

Emma Hague is a healthcare entrepreneur and investor. A2024 Carmo Companies speaker biography identifies her as a private wealth holder and general partner at ACPHealthtech. It describes founding and selling a human-data analytics business to IQVIA, and later direct and family-office healthcare investing, advising and board work. The affiliation is retained with its dated2024 evidence; current2026 tenure is unconfirmed. Her genuine portrait is the original image in that organizer biography.

Camilo Rico is an Accelmed principal with healthcare consulting, investing and investment-banking experience. His earlier employers include SFW Capital Partners, Citi’s healthcare investment-banking group and L.E.K. Consulting. He earned business and international-studies graduate degrees at the University of Pennsylvania and an undergraduate degree at Boston College.

Ilan Ben-Oren is Accelmed’s chief technology officer. He brings medical-technology research, development and management experience, including earlier technology leadership at Exalenz Bioscience. His career covers medical-device product development and clinical technologies.

Susan Alpert is Accelmed’s chief regulatory officer. Her earlier work includes senior regulatory leadership at Medtronic and C.R. Bard and FDA device-evaluation leadership. Her qualifications include medical microbiology and medicine, with experience in pediatric infectious disease and clinical research.

Guy Ohad is Accelmed’s chief medical officer and a radiologist with medical-device and technology experience. He previously led POP Medical Solutions, later FEMSelect, and held clinical and business-development responsibilities at Orex. He earned his medical degree at Tel Aviv University.

Irit Yaniv is an Accelmed venture partner whose published biography specifically describes responsibility for the historic Accelmed Ventures portfolio. She co-founded Digma Medical and NitiNotes and is a co-founder and chair of Almeda Ventures. She is a physician with an MBA from Tel Aviv University.

Daniel Cohen is an Accelmed venture partner, formally joining in2022 after more than a decade of work with the firm. His healthcare investment work includes an independent investment consulting business and leadership of Fosun Pharma in Israel. He studied applied mathematics and computer engineering and earned an MBA at ESSEC.

Stephen Rubin is an Accelmed general partner. Previously he co-led Proskauer’s private-equity practice, advising on acquisitions, private-equity and debt offerings and financing transactions. He studied law at Columbia and earned an undergraduate degree at Cornell.

Uri Geiger founded Accelmed and is its managing partner. He previously built Exalenz Bioscience and GalayOr Networks and co-founded the Dragon Variation Fund. His experience spans healthcare company leadership, investing and capital markets; he earned a doctorate at Columbia University and previously taught private equity and venture capital at Tel Aviv University.

Published name: Jeff Weiss. This profile refers to Clean Energy Ventures. Existing same-name identities and their affiliations are preserved.

Published name: Matt Cohen. This profile refers to Clean Energy Ventures. Existing same-name identities and their affiliations are preserved.

Florence Lambert is president and chief executive officer of Genvia, the solid-oxide hydrogen-electrolysis technology company, and previously led CEA-Liten. OCCTE announced her as chair of its consultative committee in December 2022; continuing committee tenure is not separately verified.

Marine Hugot is an investment analyst at OCCTE, as named in its current public team directory. A detailed biography is not published on that directory.

Romain Arette-Hourquet is an investment manager at OCCTE. Trained as an engineer at École des Mines de Paris, he previously worked at Stoa Infra & Energy and developed and financed renewable-heat and energy-efficiency projects at Kyotherm.

Audrey Laffaille is OCCTE’s head of ESG, as named in its current public team directory. A detailed professional biography is not published on that directory.

Julien Gomis is an investment director at OCCTE with experience in industrial private equity, corporate financing and financial audit. His published biography describes aerospace investing, Bpifrance financing work in Occitanie and audit and transaction-services assignments.

Jérôme Lavinaud is an investment director at OCCTE specializing in renewable energy. He previously led energy-transition investing at Sofilaro Gestion and helped establish Crédit Agricole Languedoc’s new-energy investment activity and Calen in 2010.

Emmanuelle Ostiari is an investment director at OCCTE with a background in sustainable-development research, ESG and private-equity investing. Her published biography identifies prior private-equity investment work at Mirova and low-carbon and green-technology research at Kepler.

Anne-Laure Beuscart is an investment director at OCCTE with experience financing renewable-energy and infrastructure projects. Her prior work includes renewable-energy development at MIDI 2i and financing energy, social-infrastructure and telecom projects at Natixis Global Infrastructure & Projects.

IGO Innovation managing director since 2023, also known as Axel Melchior, as verified in his issuer-published Porr biography.

IGO group executive named as CEO of IGO Innovation in UpNano’s issuer financing announcement.

Marketing and communications professional supporting investor relations since December 2024.

Supports fund management in organizational matters, reporting and controlling; her own biography dates joining to 2015.

Joined the own published team in 2026 after startup operations and community-management work in Graz.

Investment professional with auditing, banking and M&A experience, and accounting and finance studies at WU Vienna.

Corporate finance professional with transaction and restructuring advisory experience.

Fund and portfolio professional with prior risk control, fund controlling and auditing experience.

Investment professional with corporate innovation experience at weXelerate and strategy and innovation studies at Maastricht University.

Former founder of FRYNX and investment manager at Peak Pride, with strategy and innovation studies at WU Vienna.

Investment professional with prior PwC Deals Advisory experience; the own biography dates his managing-director appointment to December 2023.

Corporate finance, banking and restructuring executive responsible for fund management since 2019.

Venture capital and biotechnology executive. His own biography describes EUCODIS Bioscience leadership and deep-tech investment experience at ARAX Capital Partners.

Glenn Micallef is Commissioner for Intergenerational Fairness, Youth, Culture and Sport in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees intergenerational fairness, youth, culture and sport. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Christophe Hansen is Commissioner for Agriculture and Food in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees agriculture and food policy. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Apostolos Tzitzikostas is Commissioner for Sustainable Transport and Tourism in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees sustainable transport and tourism. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Michael McGrath is Commissioner for Democracy, Justice, the Rule of Law and Consumer Protection in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees democracy, justice, the rule of law and consumer protection. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Ekaterina Zaharieva is Commissioner for Startups, Research and Innovation in the European Commission’s current2024–2029 College, which entered office on1December2024. She oversees startups, research and innovation, including public support for scientific and technological development. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Dan Jørgensen is Commissioner for Energy and Housing in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees energy and housing policy. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Piotr Serafin is Commissioner for Budget, Anti-Fraud and Public Administration in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees the EU budget, anti-fraud measures and public administration; the EU budget is a public appropriation framework, not a private LP fund close. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Jessika Roswall is Commissioner for Environment, Water Resilience and a Competitive Circular Economy in the European Commission’s current2024–2029 College, which entered office on1December2024. She oversees environment policy, water resilience and circular-economy competitiveness. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Magnus Brunner is Commissioner for Internal Affairs and Migration in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees internal affairs and migration. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Hadja Lahbib is Commissioner for Equality Preparedness and Crisis Management in the European Commission’s current2024–2029 College, which entered office on1December2024. She oversees equality, preparedness and crisis management. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Maria Luís Albuquerque is Commissioner for Financial Services and the Savings and Investments Union in the European Commission’s current2024–2029 College, which entered office on1December2024. She oversees financial services and the Savings and InvestmentsUnion portfolio. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Costas Kadis is Commissioner for Fisheries and Oceans in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees fisheries and oceans policy. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Jozef Síkela is Commissioner for International Partnerships in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees international partnerships and development cooperation. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Marta Kos is Commissioner for Enlargement in the European Commission’s current2024–2029 College, which entered office on1December2024. She oversees EU enlargement and the accession process. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Andrius Kubilius is Commissioner for Defence and Space in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees defence and space, including the industrial and technological capabilities needed for European security. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Wopke Hoekstra is Commissioner for Climate, Net Zero and Clean Growth in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees climate policy, net-zero transition and clean growth. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Olivér Várhelyi is Commissioner for Health and Animal Welfare in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees health and animal-welfare policy, including the public-health and regulatory environment in which biotechnology and medical innovation operate. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Dubravka Šuica is Commissioner for Mediterranean in the European Commission’s current2024–2029 College, which entered office on1December2024. She leads the Mediterranean portfolio and regional partnership responsibilities. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Valdis Dombrovskis is Commissioner for Economy and Productivity Implementation and Simplification in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees economic policy, productivity, implementation and simplification of EU rules. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Maroš Šefčovič is Commissioner for Trade and Economic Security Interinstitutional Relations and Transparency in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees trade and economic security and the Commission’s interinstitutional relations and transparency responsibilities. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Raffaele Fitto is Executive Vice-President for Cohesion and Reforms in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees cohesion and reforms, including regional development and reducing economic and territorial disparities. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Roxana Mînzatu is Executive Vice-President for Social Rights and Skills, Quality Jobs and Preparedness in the European Commission’s current2024–2029 College, which entered office on1December2024. She coordinates social rights, skills, quality employment and preparedness, including workforce skills and education policy. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Kaja Kallas is High Representative for Foreign Affairs and Security Policy Vice-President in the European Commission’s current2024–2029 College, which entered office on1December2024. She leads EU foreign and security policy and contributes as a Commission Vice-President; this diplomatic role is distinct from an individual company investment. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Stéphane Séjourné is Executive Vice-President for Prosperity and Industrial Strategy in the European Commission’s current2024–2029 College, which entered office on1December2024. He coordinates industrial strategy, the single market, SME competitiveness and investment in strategic technologies, including clean manufacturing and critical raw materials. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Henna Virkkunen is Executive Vice-President for Tech Sovereignty, Security and Democracy in the European Commission’s current2024–2029 College, which entered office on1December2024. Her portfolio includes AI innovation, digital and frontier technologies, high-performance computing, cloud infrastructure, quantum technologies and enforcement of digital-market and online-platform rules. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Teresa Ribera is Executive Vice-President for Clean, Just and Competitive Transition in the European Commission’s current2024–2029 College, which entered office on1December2024. She coordinates the green transition, industrial decarbonisation and clean-technology investment, and oversees competition policy, state aid, merger control and DigitalMarketsAct enforcement. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Ursula von der Leyen is President of the European Commission in the European Commission’s current2024–2029 College, which entered office on1December2024. She leads the Commission and its political priorities, having first become Commission President in2019 and secured a second mandate inJuly2024. Her own October2026 agenda confirms continuing service. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Catherine Juillard is named in Dassault Systèmes’ current official investor-contact directory. The directory establishes an investor-relations contact affiliation, without publishing a more specific position, career history or education. No authentic original portrait was verified in the retrieved primary directory. The affiliation is not an investment-partner role or a personal company check.

Delphine Da Maia-Levy is named in Dassault Systèmes’ current official investor-contact directory. The directory establishes an investor-relations contact affiliation, without publishing a more specific position, career history or education. No authentic original portrait was verified in the retrieved primary directory. The affiliation is not an investment-partner role or a personal company check.

Michele de Souza is named in Dassault Systèmes’ current official investor-contact directory. The directory establishes an investor-relations contact affiliation, without publishing a more specific position, career history or education. No authentic original portrait was verified in the retrieved primary directory. The affiliation is not an investment-partner role or a personal company check.

Julien Mouret is named in Dassault Systèmes’ current official investor-contact directory. The directory establishes an investor-relations contact affiliation, without publishing a more specific position, career history or education. No authentic original portrait was verified in the retrieved primary directory. The affiliation is not an investment-partner role or a personal company check.

Isabelle Fuzellier is named in Dassault Systèmes’ current official investor-contact directory. The directory establishes an investor-relations contact affiliation, without publishing a more specific position, career history or education. No authentic original portrait was verified in the retrieved primary directory. The affiliation is not an investment-partner role or a personal company check.

Marie Dumas is named in Dassault Systèmes’ current official investor-contact directory. The directory explicitly identifies her as Investor Relations Director. No authentic original portrait was verified in the retrieved primary directory. The affiliation is not an investment-partner role or a personal company check.

Christine Defert is a Dassault Systèmes employee-representative director appointed by the CFDT union. She has been an executive assistant in its Industries organization since2007 after office-management and assistant roles at French startups. She served on the French works council and as its deputy board representative2017–2024 and on the European committee2020–2024. Her own profile also identifies CFDT metallurgy-union executive membership and labor-court judicial service since2023.

Anne-Laure Chevalier is a Dassault Systèmes employee-representative director appointed by the CFE-CGC union. She has led legal development and organization since2018, following legal special projects and deployments from2010 and progressively senior contract/legal roles1992–2010. She joined the company’s documentation-translation team in1990. She has a postgraduate English and American business-law qualification from Paris I Panthéon-Sorbonne.

Eric Trappier is a Dassault Systèmes director, GIMD chairman since2025 and Dassault Aviation chairman and CEO since2013. An engineer educated at Sud Telecom, he joined Dassault Aviation in1984 and progressed through technical, sales, regional and international leadership positions. His own current biography identifies additional Dassault-group boards and aerospace/industrial association roles. Dassault Aviation and GIMD remain distinct from the software parent; his group offices do not imply personal Click cash participation.

Donatella Sciuto is an independent Dassault Systèmes director, rector of Politecnico di Milano and professor of information-processing systems. She studied electronic engineering, earned an electrical/computer-engineering PhD from the University of Colorado Boulder and a Bocconi MBA. Her own biography reports more than400 scientific articles and four international patents, IEEE electronic-design-automation leadership, Academia Europaea membership and recognition for women’s AI leadership. She promotes STEM inclusion and holds additional Italian corporate and institutional governance roles.

Nathalie Rouvet Lazare is an independent Dassault Systèmes director with strategy, marketing, corporate-management and governance experience. An HEC graduate and IFA/Sciences Po-certified director, she worked at Air France, Saatchi & Saatchi, Publicis and La Poste. She became a Coheris director in2011 and led that software company as chairman and CEO2013–2019, including its turnaround and takeover. Her current own profile identifies an independent Hightech Payment Systems directorship and committee roles.

Marie-Hélène Habert-Dassault is a Dassault Systèmes director and leads communication and patronage at Groupe Industriel Marcel Dassault. She joined GIMD in1991 after working in London media planning at DDB Publicité. She has postgraduate corporate-law and taxation studies from Assas and a strategy/marketing master’s from Sciences Po. Her own current biography identifies governance roles at GIMD, Dassault Aviation, Serge Dassault Foundation, Biomérieux and research foundations. Corporate and family affiliations do not prove personal investments.

Olivier Costa de Beauregard represents corporate director Groupe Industriel Marcel Dassault on Dassault Systèmes’ board; the legal director is GIMD rather than the individual in a separate personal voting seat. He has been GIMD CEO since2006 after joining as deputy CEO in2005. He previously worked in France’s financial inspectorate, the prime minister’s office, UAP/AXA and Crédit Commercial de France/HSBC. His own board biography identifies senior French public-administration and policy education and multiple group governance affiliations.

Soumitra Dutta is an independent Dassault Systèmes director and scientific-committee chair. He founded and leads Portulans Institute and is a founding general partner of Green Frontier Capital. With a computer-science doctorate, he worked at UC Berkeley, General Electric and INSEAD, where he established eLab and served in dean roles. He subsequently held Cornell business-school leadership2012–2018 and was dean of Oxford’s Saïd Business School2022–2025. The current own biography qualifies the Oxford appointment as former, not current.

Laurence Daures is Dassault Systèmes’ lead independent director. She is an ESSEC finance professor and CREST-affiliated researcher, with a finance doctorate from HEC Paris and postgraduate degrees from EDHEC, Paris Dauphine and Paris School of Economics. Her work addresses capital-market organization and regulation. She previously led ESSEC’s finance department and taught at ENSAE; her research received the2013 Vega Prize and a2015 derivatives-research award. Her own profile identifies an independent LCL directorship and audit-committee leadership.

Catherine Dassault is a Dassault Systèmes director. She leads development at Institut de l’Engagement, supporting education, employment and entrepreneurship for young people completing France’s Civic Service program. She studied law and psychology and previously worked in advertising and communications before focusing on medical research and education philanthropy. Her own profile identifies Fondation AP-HP, Green Spark Invest, TCBD & Fils and Fonds de dotation Citadelle affiliations; no personal company subscription is inferred.

Xavier Cauchois is an independent Dassault Systèmes director and audit-committee chair. He spent more than thirty years in audit and consulting as a PwC France partner, working across technology, telecoms, media, healthcare and industry. He led PwC’s European and French technology-sector practice until2009, served on its global audit strategy committee2005–2008 and its French executive committee2013–2016. His current own profile also identifies a Temenos directorship.

Geneviève Berger is an independent Dassault Systèmes director and its lead director for sustainable development. A physician with a human-biology doctorate, she founded an imaging laboratory at CNRS and Broussais Hôtel-Dieu in1991, headed CNRS2000–2003 and worked at La Pitié-Salpêtrière2003–2008. She later led research at Unilever2008–2014 and Firmenich2015–2021. Her own current board profile also identifies Kerry Group, Institut Curie and Paris-Saclay governance affiliations.

Charles Edelstenne founded Dassault Systèmes and is identified in its current own biography as honorary chairman and director. He led the company as manager1981–1993, chairman and CEO1993–2002, then board chairman untilJanuary9,2023. He is also honorary chairman of Groupe Industriel Marcel Dassault and Dassault Aviation, where he previously held senior financial and executive roles. He has a chartered-accountant qualification. These distinct group businesses are not aliases for the software company.

Hector Edwards is an OTIF Ventures associate focused on life-sciences investments, joining in2023. The current native directory identifies previous NHS medical practice, Nottingham medical degrees and impact-investment advisory work at New Philanthropy Capital. His company board and observer affiliations are distinct from manager employment.

Alexander Chamberlain is OTIF Ventures Senior Associate, joining in2019 and focused on deep technology and clean technology. His biography describes New Street Research and Seraphim Capital experience, an Edinburgh physical-geography degree, and separately qualified board/observer affiliations.

William Middleton is an OTIF Ventures principal. His biography describes prior Sloane Robinson investment analysis and a separate Technikos biomedical-engineering portfolio-management role. He holds a Melbourne history degree and has Oxford spinout board affiliations; no outside fund is merged into OTIF.

Tania Wilson is OTIF Ventures Principal and CFO. She previously worked in valuation and corporate finance, including PwC. The company biography identifies her as a Chartered Management Accountant with Oxford economics and Cambridge mathematics degrees, joining the manager in early2019.

James Mallinson is an OTIF Ventures partner, having joined inJanuary2018 after managing Oxford’s spinout equity portfolio. His biography describes engineering/software work, Oxford Engineering Science and a Cranfield MBA. University-period shareholdings are distinct from OTIF manager investments.

Ross Hyett is an OTIF Ventures founding partner. The manager biography also identifies him as Ocean Infinity founder and Windsor Private Office senior partner, with entrepreneurial fundraising and prior British Racing Drivers’ Club leadership. Those outside affiliations are not OTIF employees or personal portfolio cash checks.

Christopher Delafield Hall is an OTIF Ventures partner, identified by the exact Companies House legal member record. The current manager biography describes telecommunications, corporate finance and law, including his former Latham & Watkins partnership. The existing Mobio Interactive growth professional Christopher Hall has a different published career and remains separate.

George Robinson is a founding partner of OTIF Ventures and co-founder of Sloane Robinson. His company biography describes Asian equity-research work, Oxford Engineering Science studies and early-stage technology/biotechnology investing. His personal2008 spinout investments are distinguished from later manager transactions.

Marco Gullà is named as HTH InvestmentAssociate and a member of the team coordinating Zcube’s OpenAccelerator in the February2024 primary launch. HTH is the program’s separate operational partner; this role records a source-proven program affiliation and does not assert statutory Zcube employment. His own public2024 post discusses the program’s conditional SAFE offer, and his own2022 post confirms HTH investor-event jury participation.

Michele Gaiotto, CEO of the separate HTH HealthTechnologyHolding, is a Zcube adviser and coordinator in its February2024 launch. His March22,2024 own program interview identifies him as leading operating partner overseeing women’s-health, central-nervous-system and digital-medicine investments. HTH external partnership does not establish a shared legal manager or that every HTH portfolio company received Zcube cash.

Vittoria Pavoncello is a biotechnologist and neuroscientist. Zcube’s February2024 launch identifies her as Technology Scouting and Investment Specialist and program coordinator. Her2025 LifeSciencesBaltics speaker biography confirms Zcube InvestmentAssociate and managing OpenAccelerator’s women’s-health program. The current2026 Informa investor-conference speaker listing also identifies her as InvestmentAssociate at Zcube ventures; the future conference itself has not yet occurred.

Federica Destro was named Zcube External Innovation and Community Manager and OpenAccelerator coordinator in the February2024 primary launch and her March22,2024 own program interview. Her work encompasses external innovation, life-sciences entrepreneurs and the prior accelerator editions. The currently replaced program site does not establish a complete2026 employment roster.

Elena Zambon is creator of Open Accelerator and chair of Zambon, as identified by the February and September2024 program announcements. This program-creator affiliation is distinct from an asserted Zcube statutory office or personal cash investment. Current ownparent leadership and the separate Zoé foundation identify her leadership roles.

Giovanni Magnaghi was president of Zcube and Zambon CFO in the February27,2024 program launch. The later September2024 Zcube announcement names Andrea D’Alessandro as president. Exact Zcube departure day is unknown. He became ZambonSpA CEO on May2,2024 and remains listed as CEO in current parent leadership; the older CFO portrait page is used for authentic identity only.

Andrea D’Alessandro is identified as president of Zcube in its September24,2024 HyivyHealth financing announcement, superseding the earlier February2024 president. Zambon’s current corporate leadership directory separately identifies him as Chief Compliance Officer. These are separate corporate affiliations; no automatic statutory directorship or personal check is inferred.

Barbara Lucini has held the published role of HR Director of Generali Welion and People Value & Engagement leader for Generali Italia. Her primary professional speaker biography describes experience in organisational culture, change management, leadership development, organisational design, employee welfare, recruitment and employer branding. It records work on inclusion and initiatives supporting girls’ participation in science and technology. The current parent management directory names a sustainability and social-responsibility role; the reviewed Welion HR affiliation is therefore retained as historical rather than automatically assumed current.

Cristina Rustignoli is Generali Italia’s Country General Counsel and a publicly documented member of Generali Welion’s board. Primary Generali transaction disclosure and her professional speaker biography identify this direct Welion governance affiliation alongside board and legal responsibilities elsewhere in the group. Her work includes corporate governance, legal coordination and insurance-company integration. The Welion board affiliation is source-qualified because its exact current term is not published in the company’s reviewed2025 governance model; parent legal duties do not independently establish every subsidiary appointment.

Ivano Bosisio was assigned Operations & Customer Excellence at Generali Welion in the company’s2017 launch announcement. The function supported delivery of the new integrated health and welfare services. His own later professional communication describes Welion’s collaboration with Generali Italia’s Smart Process Automation team using artificial intelligence and optical character recognition to automate processes. The primary role is historically documented; his present Welion appointment, education and a named original portrait remain unverified.

Andrea Mencattini led Generali Welion as chief executive officer at its2017 public launch, according to the company’s primary announcement. His remit centred on integrated welfare, health services, employee benefits and startup-enabled service development. An earlier official Generali biography records his joining the group in1986 and chief executive appointment at Europ Assistance Italia in2006 before leading the Italian insurance business. His Welion affiliation is retained as historical; current appointment and exact tenure end are not asserted.

Cesare Lai previously served as chief executive officer and general manager of Generali Welion. His own primary speaker biography identifies aMarch1,2021 appointment and his oversight of the company’s health and welfare services and employee-benefit insurance operations. The parent’sMay25,2022 announcement names Paolo De Santis as his successor effectiveJune1,2022. The role is historical and is not presented as a current Welion leadership appointment. A genuine named portrait is published in the primary event biography.

Paolo De Santis was appointed chief executive officer and general manager of Generali Welion effectiveJune1,2022, replacing Cesare Lai, according to the parent’s exactMay25,2022 announcement. At appointment he was already Chief Health & Welfare Officer of Generali Country Italia, with extensive group experience in insurance and health. Current company communications name Francesco Bardelli as CEO, so this Welion role is explicitly historical; the exact later succession day is not invented. A separate2019 primary organisational announcement had also named De Santis as Welion executive director during interim management.

Venture operations professional.

Compliance, audit and regulatory-risk professional with a decade of experience.

Finance professional with more than 15 years across finance and operations functions.

Creative director and communications professional with 14 years of marketing experience.

Finance and operations professional with more than 20 years of startup finance and regulatory-compliance experience.

Holds a Ph.D. in computational biology and has nearly a decade of experience in the US research ecosystem.

Technology entrepreneur and investor with more than 15 years in AI, media technology and education technology.

Deep-tech investor with 30 years of experience in multinational technology companies and startups. Published nickname Karthik.

Chairman of Florintree Advisors with private-equity and corporate leadership experience.

Over 35 years of deep-tech experience, including entrepreneurship and investing.

Andrea Quarta is identified in his own public professional activity as responsible for Planning and Development at Generali Welion. He represents the company’s work on its health-services ecosystem and customer experience, alongside Health & Welfare Marketing colleagues. His exact ownprofile slug12569b5b distinguishes this insurance-services professional from hospitality and technology professionals with the same name. Education, detailed career history, role start day and an authentic portrait remain unverified.

Francesco Gelosa works in health and welfare marketing at Generali Welion. Primary2024 programme material identifies him within the company’s Health & Welfare Services and Marketing function, and Welion’s2025 business-cascading communication names his participation in the Attiva Welfare discussion covering health services and home assistance for caregivers and vulnerable people. His own professional profile confirms the company affiliation and study at MIB Trieste School of Management. Exact current managerial seniority and appointment dates are not inferred from secondary organisation charts.

Giulia Franceschi is responsible for Medical Network Management at Generali Welion, as named in the company’s own2025 event announcement and2026 communications. Her public work concerns the healthcare-provider network, integration of medical appointment systems and digital access to care for insured clients. Her own professional profile identifies Generali Welion and business-school education at New York University’s Stern School of Business; broader biographical details and an original named portrait remain unverified.

Barbara Ambrogioni heads Health & Welfare Services and Marketing at Generali Welion. She has more than20years of experience in health and welfare, insurance brokerage and human-resources consulting. Since joining Generali in2018 she has helped define B2B and retail welfare services for the open market and supported group insurers’ health and protection offerings. Her primary professional biography records economics and actuarial studies at Sapienza University of Rome and a master’s in Insurance & Risk Management at MIB School of Management. Welion’s2026 company event communications confirm her current service and marketing responsibilities.

Nicola Meliddo is the named chairman and internal member of Generali Welion’s Organismo di Vigilanza in its current official governance disclosure. The supervisory body oversees implementation and effectiveness of the company’s organisational and compliance model under Italian Legislative Decree231/2001. The2025 model describes the oversight system and internal-control reporting responsibilities. A wider professional career, education and genuine portrait are not published in the reviewed primary disclosure.

Gianluca Perin is chairman of Generali Welion and Country General Manager of Generali Italia, as identified in the parent’s current official biography. He studied business economics at Università Bocconi. His career included human-resources leadership at RCS, Mondadori and Il Sole24Ore before joining Generali in2012 as HR director for Alleanza Toro. He became Generali Italia’s Chief HR & Organization Officer in2013 and Country General Manager inSeptember2022. This is a source-proved Welion governance appointment; other parent managers are not automatically assigned to Welion.

Francesco Bardelli leads Generali Welion as chief executive officer and general manager and is Generali Italia’s Chief Health & Welfare and Broker Management Officer. His responsibilities connect health and accident insurance, integrated welfare services and strategic development. Primary speaker material records engineering studies at Politecnico di Milano and an MBA at SDA Bocconi, earlier international transformation work at McKinsey and SIA, and his2013 entry into Generali. He subsequently worked on Italian insurer integration, business transformation, connected insurance at Generali jeniot and the Cattolica integration. Welion’s2026 company communications confirm his current CEO appointment; an older2022 release appointed Paolo De Santis, so Bardelli’s exact succession day remains unclaimed.

Cambridge-trained biochemist with crop-protection and disease-resistant crop development experience.

Environmental-science and data-analytics professional with marine ecosystem management and mathematics degrees.

PwC-trained chartered accountant with manufacturing, fertilizer and technology finance experience.

Venture investor and company builder in agriculture, green chemistry, advanced materials and enterprise software; trained in physical chemistry.

Ardena COO and ChemConnection founder with experience building drug-development and manufacturing businesses.

Henlius senior vice president and chief business officer with biopharmaceutical partnerships, manufacturing and business-development experience.

Clinical pathologist, former AML laboratory entrepreneur and Heran Partners founding partner advising on life-sciences investing.

Chemistry, manufacturing and controls specialist with more than 20 years in Synthon research and development leadership.

Life-sciences and health-technology leader supporting portfolio strategy, governance, partnerships and international growth.

Precision-health investor with an Oxford DPhil in genetics and neuroscience and earlier investment-banking experience at Morgan Stanley, Altium Capital and Arctic Securities. Her PAACS investor/co-chair title is self-described in an April 2023 interview; it is distinct from the current legally registered chair.

Christoph Bartoschek is named by EITHealth as the Aescuvest contact for its2021 crowdfunding investment-readiness programme. A2025 PIURImaging issuer release names him as investment principal at AescuvestCapitalPartners, the related but distinct fund-manager business. The Aescuvest platform affiliation is source-qualified historical; no automatic current platformemployment or legalACPmanagerrole is created here. A genuine individual portrait remains unverified. ACP-specific affiliation: Christoph Bartoschek is identified as Investment Principal in ACP’s January2025 launch release and PIURImaging’s July2025 financing announcement. His own current public professional profile names ACPHealthtechManagementGmbH. This is distinct from his historical Aescuvest platform programme-contact work.

David Cubbin is an investor and business operator. His own2025 announcement records joining Aescuvest as a partner. His2026 announcement describes founding the separate FerysCapital with SebastianGührs and places his Aescuvest partner work in his prior career alongside ChallengerEMEA and CureCapital. This profile preserves the actual historicalAescuvestappointment without claiming ongoing2026tenure or mergingFerys with Aescuvest. An authentic individual portrait remains unverified. ACP-specific qualified affiliation: Patrick Pfeffer’s public reply to DavidCubbin’s2025 Aescuvest appointment announcement welcomes him to work at both Aescuvest and ACPHealthtech. That supports an investment-team collaboration, but does not disclose an ACP-specific legal partner appointment. David’s2026 FerysCapital launch is separate. This record uses a historical collaborator title, not a guessed currentACPpartnerrole.

Sebastian Gührs is a healthcare venture investor. Primary2023 Neteera financing announcements and a2024 conference biography name him as partner and head of investment at Aescuvest. In his2026 self-authored announcement, he refers to his past years at Aescuvest and launches the separate FerysCapital with DavidCubbin. This Aescuvest role is retained as a qualified historical affiliation rather than asserted as current. The authentic original portrait is extracted from the2024 Carmo organizer speaker biography. ACP-specific historical affiliation: The2024 Carmo organizer biography labels Sebastian Gührs Partner and Head of Investment at ACPHealthtech/Aescuvest. Subsequent2026 first-person announcements describe founding the separate FerysCapital with DavidCubbin and priorAescuvestcareer. His historical ACP title is qualified rather than asserted as ongoing2026 employment.

Olivier Gracia identifies himself in his April2026 own biography as CFO at Aescuvest and separately CFO and general partner at ACPHealthTech. His career includes product and growth work at Eurosport and WebMD Europe, followed by information management and marketing work at Aescuvest. The current CFO role supersedes older directoryCMO wording; ACPHealthTech is a distinct legal manager. His portrait is published on his own current biography. ACP-specific affiliation: Olivier Gracia’s signed April2026 biography and venture page identify him as CFO and general partner at ACP HealthTech, separately from CFO at the Aescuvest platform. The named ownlinks bridge this actualACPmanagerdomain. These distinct roles are retained without migrating either organization’s investment checks.

Patrick Pfeffer founded Aescuvest in2014 and is named on its current ownsite as managing partner and legal managing director. He previously worked in health-media and digital strategy, including WebMD/Medscape European expansion. His primary interview describes his healthcare crowdfunding approach; his2025 personal announcement distinguishes the Aescuvest deal-by-deal platform from the separately launched ACPHealthtech fund business. The genuine portrait is from his dated2015 firsthand interview, not presented as a newly photographed2026 image. ACP-specific affiliation: Patrick Pfeffer is named as managing partner in ACP’s own January2025 launch announcement. His own launch post describes forming this fund manager separately from the Aescuvest deal-by-deal platform, and his later first-close announcement confirms actual LP backing without disclosing fund size or closing day.

Andreas Werner is a U2V venture partner and technology entrepreneur. He co-founded industrial location-systems company Agilion, which Siemens acquired, and subsequently supported its RTLS technology.

Moritz von Klot is a U2V principal whose investing experience spans Earlybird-X, university commercialisation and climate technology. He studied mechanical engineering and finance.

Pharmacist, entrepreneur and business angel with experience in healthcare, pharmaceuticals, medical technology and company boards.

Pharmacist and entrepreneur with pharmaceutical sales and marketing experience, including Pfizer; co-built Netdoktor and has worked in medical education.

Nurse and market economist with experience building Netdoktor, healthcare operations, entrepreneurship and life-science angel investing.

Previous experience at Oberoi Hotels and Resorts and Flyhomes.

Former Slush global expansion professional and founding team member of a Finnish deep technology fund.

Chartered accountant.

Chartered accountant with previous experience at JPMorgan Chase.

Chartered accountant with a decade of finance and accountancy experience.

Former India general manager at Flyhomes, with prior Fidelity experience and an integrated MTech from IIT Delhi.

Previously a venture partner at Octopus Ventures in Singapore.

Investment and strategy professional with previous experience at Bessemer Venture Partners, Ola Electric and Piaggio corporate venture capital.

Finance executive with previous experience at Peak XV Partners and Premji Invest.

Serial entrepreneur and co-founder of Sunstone.

Founder of Purvi Capital and co-founder of Jump Trading’s high-frequency trading group.

Healthcare and education entrepreneur who leads Leo Capital’s investments outside India.

Entrepreneur who founded Pine Labs, GlobalLogic and Sunstone, with early angel investments including Meesho, 1mg and Reify Health.

Law and economics graduate with more than 15 years in international law firms working on acquisitions, financing rounds and company law; joined the university investment function in 2017.

Finance graduate with nearly ten years of investment banking experience before joining the University of Helsinki investment function in 2019.